Shire target Baxalta nabs FDA nod for long-acting Adynovate; Novo CEO vows to defy diabetes gloom-and-doom;

@FiercePharma: Bioprinting winning converts in Singapore. FiercePharmaAsia item | Follow @FiercePharma

@EricPFierce: ICYMI: Roche whacking 1,200 jobs, closing plants in US, Ireland, Italy and Spain, but building one in Switzerland. Story | Follow @EricPFierce

@CarlyHFierce: Boehringer ups the ante in IPF drug race with awareness funding. More from FiercePharmaMarketing | Follow @CarlyHFierce

> Baxalta ($BXLT) won FDA approval for its long-acting hemophilia A drug Adynovate, which the company hopes will help boost sales despite increasing competition in the field. Report | More

> Novo Nordisk ($NVO) "has never been in a better position," despite rivals' warnings about insulin sales slumps, CEO Lars Rebien Sørensen said in an interview. Report

> Sweden's Meda, whose dermatology drug Elidel is licensed in the U.S. to Valeant Pharmaceuticals ($VRX), could see sales disruptions from its partner's specialty pharmacy woes. Report

Medical Device News

@FierceMedDev: ICYMI: Crime syndicates are hacking devices to steal private medical information for profit. Article | Follow @FierceMedDev

@VarunSaxena2: @HillaryClinton says Medicare should negotiate for lower drug prices. @BernieSanders rips Big Pharma, too. Uh oh! | Follow @VarunSaxena2

@EmilyWFierce: Gilead scores additional indications for Harvoni in hep C, HIV patients. FiercePharma story | Follow @EmilyWFierce

> J&J to launch suite of orthopedics 'solutions' for outpatient joint replacement. Report

> SurgiQuest snapped up for $265M ahead of proposed IPO, rounding out Conmed surgical offerings. Article

> Omada Health trumpets promising results from study of digital health program in Medicare patients. More

Biotech News

@FierceBiotech: RIP: Failure-prone KaloBios pulls the plug, calls in the liquidators. More | Follow @FierceBiotech

@JohnCFierce: Did Sanofi ($SNY) drag its feet on Lemtrada to save on the CVR? (Or is it just a lousy drug?). More from the NYT | Follow @JohnCFierce

@DamianFierce: Bloomberg's use of up-style headlines has resulted in a piece of art. Item | Follow @DamianFierce

> Moving on from Novartis, Array inks a $455M oncology deal with Pierre Fabre. Report

> Baxalta wins FDA OK for a long-acting Advate, padding its hemophilia biz. News

> Clovis craters after lung cancer drug hits FDA road block, data deteriorate. Article

Animal Health News

> Heska beats the Street on revenue and earnings in Q3. More

> Aratana unveils branding and partnering plans at investor day. Report

> Merck reiterates dedication to animal health with Harrisvaccines acquisition. Article

> Phibro seeks growth in aquaculture as Q1 sales growth slows. Story

> ImmuCell soars on Q3 sales growth. Item

Biotech IT News

> Datatrak accused of 'shameless and amateurish scare tactics' as proxy fight turns nasty. Report

> What represents success to 23andMe's Wojcicki? Developing a cure for a major disease. More

> WuXi NextCODE lands starring role in 100,000 Genomes Project. Story

> FDA starts beta testing 'the most advanced bioinformatics platform in the world.' More

> Data-gathering implantable chips to be tested in schizophrenia trial. Article

Pharma Marketing News

> Depomed's staffed-up Nucynta salesforce starts bringing home the bacon. Report

> Merck to forge ahead with CETP-inhibiting cholesterol med. Item

> *NSYNC's Joey Fatone lends pearly whites to Colgate diabetes campaign. Story

> Snafus waiting to happen? Pharma's digital silos stymie end-to-end promo management. More

> Boehringer ups the ante in IPF drug race with awareness funding. Article

And Finally... GlaxoSmithKline ($GSK) is readying new regulatory submissions for its injectable form of the lupus drug Benlysta. Report

Suggested Articles

Former Indivior CEO Shaun Thaxter will face six months in federal prison for his role in misleading government officials on the dangers of Suboxone.

As of Friday after local time, 36 people have died in Korea after getting flu shots provided by at least seven companies, including Sanofi.

Two prominent pneumococcal vaccines from Merck and Pfizer are running low in Europe in a possible ill omen for the coming winter: report.